Novel combination therapy for human colon cancer with adenovirus- mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent

Nobuyuki Ogawa, Toshiyoshi Fujiwara, Shunsuke Kagawa, Masahiko Nishizaki, Yoshinori Morimoto, Tohru Tanida, Akio Hizuta, Tutsuji Yasuda, Jack A. Roth, Noriaki Tanaka

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Alteration of the wild-type (wt) p53 gene by mutation, deletion or re- arrangement is a major factor in the development of human colon cancer. Recent studies have demonstrated that p53 might be an essential component of the apoptotic pathway triggered by DNA-damaging stimuli such as chemotherapeutic agents and ionizing radiation. We examined the anti-tumor effects of adenovirus-mediated wt-p53 gene transfer in combination with a chemotherapeutic drug on the human colon cancer cell line WiDr, which is homozygous for a mutation in the p53 gene. Treatment with the chemotherapeutic drug cisplatin following infection with a replication- deficient, recombinant adenoviral vector expressing wt-p53 (termed AdCMVp53) significantly suppressed the growth of WiDr cells compared to single treatments alone. To evaluate the in vivo efficacy of AdCMYp53 and cisplatin given sequentially, WiDr cells were inoculated s.c. in nu/nu mice. After 3 days, AdCMVp53 was injected s.c. into the area where tumor cells were implanted, followed by i.p. administration of cisplatin. Analysis of initial growth inhibition at 21 days demonstrated a profound therapeutic cooperativity, though administration of either AdCMVp53 or cisplatin alone was followed only by a slowing of growth. Our results suggest that gene therapy using wt-p53-expressing adenovirus in combination with a chemotherapeutic DNA-damaging drug could be a useful strategy for treating human colon cancer.

Original languageEnglish
Pages (from-to)367-370
Number of pages4
JournalInternational Journal of Cancer
Volume73
Issue number3
DOIs
Publication statusPublished - 1997

Fingerprint

p53 Genes
Adenoviridae
Colonic Neoplasms
Cisplatin
DNA
Growth
Pharmaceutical Preparations
Mutation
Gene Deletion
Human Development
Therapeutics
Ionizing Radiation
Genetic Therapy
Neoplasms
Cell Line
Transfer (Psychology)
Infection

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Novel combination therapy for human colon cancer with adenovirus- mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent. / Ogawa, Nobuyuki; Fujiwara, Toshiyoshi; Kagawa, Shunsuke; Nishizaki, Masahiko; Morimoto, Yoshinori; Tanida, Tohru; Hizuta, Akio; Yasuda, Tutsuji; Roth, Jack A.; Tanaka, Noriaki.

In: International Journal of Cancer, Vol. 73, No. 3, 1997, p. 367-370.

Research output: Contribution to journalArticle

Ogawa, Nobuyuki ; Fujiwara, Toshiyoshi ; Kagawa, Shunsuke ; Nishizaki, Masahiko ; Morimoto, Yoshinori ; Tanida, Tohru ; Hizuta, Akio ; Yasuda, Tutsuji ; Roth, Jack A. ; Tanaka, Noriaki. / Novel combination therapy for human colon cancer with adenovirus- mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent. In: International Journal of Cancer. 1997 ; Vol. 73, No. 3. pp. 367-370.
@article{adc925181442489f95932d121ac17fa7,
title = "Novel combination therapy for human colon cancer with adenovirus- mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent",
abstract = "Alteration of the wild-type (wt) p53 gene by mutation, deletion or re- arrangement is a major factor in the development of human colon cancer. Recent studies have demonstrated that p53 might be an essential component of the apoptotic pathway triggered by DNA-damaging stimuli such as chemotherapeutic agents and ionizing radiation. We examined the anti-tumor effects of adenovirus-mediated wt-p53 gene transfer in combination with a chemotherapeutic drug on the human colon cancer cell line WiDr, which is homozygous for a mutation in the p53 gene. Treatment with the chemotherapeutic drug cisplatin following infection with a replication- deficient, recombinant adenoviral vector expressing wt-p53 (termed AdCMVp53) significantly suppressed the growth of WiDr cells compared to single treatments alone. To evaluate the in vivo efficacy of AdCMYp53 and cisplatin given sequentially, WiDr cells were inoculated s.c. in nu/nu mice. After 3 days, AdCMVp53 was injected s.c. into the area where tumor cells were implanted, followed by i.p. administration of cisplatin. Analysis of initial growth inhibition at 21 days demonstrated a profound therapeutic cooperativity, though administration of either AdCMVp53 or cisplatin alone was followed only by a slowing of growth. Our results suggest that gene therapy using wt-p53-expressing adenovirus in combination with a chemotherapeutic DNA-damaging drug could be a useful strategy for treating human colon cancer.",
author = "Nobuyuki Ogawa and Toshiyoshi Fujiwara and Shunsuke Kagawa and Masahiko Nishizaki and Yoshinori Morimoto and Tohru Tanida and Akio Hizuta and Tutsuji Yasuda and Roth, {Jack A.} and Noriaki Tanaka",
year = "1997",
doi = "10.1002/(SICI)1097-0215(19971104)73:3<367::AID-IJC11>3.0.CO;2-A",
language = "English",
volume = "73",
pages = "367--370",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Novel combination therapy for human colon cancer with adenovirus- mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent

AU - Ogawa, Nobuyuki

AU - Fujiwara, Toshiyoshi

AU - Kagawa, Shunsuke

AU - Nishizaki, Masahiko

AU - Morimoto, Yoshinori

AU - Tanida, Tohru

AU - Hizuta, Akio

AU - Yasuda, Tutsuji

AU - Roth, Jack A.

AU - Tanaka, Noriaki

PY - 1997

Y1 - 1997

N2 - Alteration of the wild-type (wt) p53 gene by mutation, deletion or re- arrangement is a major factor in the development of human colon cancer. Recent studies have demonstrated that p53 might be an essential component of the apoptotic pathway triggered by DNA-damaging stimuli such as chemotherapeutic agents and ionizing radiation. We examined the anti-tumor effects of adenovirus-mediated wt-p53 gene transfer in combination with a chemotherapeutic drug on the human colon cancer cell line WiDr, which is homozygous for a mutation in the p53 gene. Treatment with the chemotherapeutic drug cisplatin following infection with a replication- deficient, recombinant adenoviral vector expressing wt-p53 (termed AdCMVp53) significantly suppressed the growth of WiDr cells compared to single treatments alone. To evaluate the in vivo efficacy of AdCMYp53 and cisplatin given sequentially, WiDr cells were inoculated s.c. in nu/nu mice. After 3 days, AdCMVp53 was injected s.c. into the area where tumor cells were implanted, followed by i.p. administration of cisplatin. Analysis of initial growth inhibition at 21 days demonstrated a profound therapeutic cooperativity, though administration of either AdCMVp53 or cisplatin alone was followed only by a slowing of growth. Our results suggest that gene therapy using wt-p53-expressing adenovirus in combination with a chemotherapeutic DNA-damaging drug could be a useful strategy for treating human colon cancer.

AB - Alteration of the wild-type (wt) p53 gene by mutation, deletion or re- arrangement is a major factor in the development of human colon cancer. Recent studies have demonstrated that p53 might be an essential component of the apoptotic pathway triggered by DNA-damaging stimuli such as chemotherapeutic agents and ionizing radiation. We examined the anti-tumor effects of adenovirus-mediated wt-p53 gene transfer in combination with a chemotherapeutic drug on the human colon cancer cell line WiDr, which is homozygous for a mutation in the p53 gene. Treatment with the chemotherapeutic drug cisplatin following infection with a replication- deficient, recombinant adenoviral vector expressing wt-p53 (termed AdCMVp53) significantly suppressed the growth of WiDr cells compared to single treatments alone. To evaluate the in vivo efficacy of AdCMYp53 and cisplatin given sequentially, WiDr cells were inoculated s.c. in nu/nu mice. After 3 days, AdCMVp53 was injected s.c. into the area where tumor cells were implanted, followed by i.p. administration of cisplatin. Analysis of initial growth inhibition at 21 days demonstrated a profound therapeutic cooperativity, though administration of either AdCMVp53 or cisplatin alone was followed only by a slowing of growth. Our results suggest that gene therapy using wt-p53-expressing adenovirus in combination with a chemotherapeutic DNA-damaging drug could be a useful strategy for treating human colon cancer.

UR - http://www.scopus.com/inward/record.url?scp=0030781397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030781397&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19971104)73:3<367::AID-IJC11>3.0.CO;2-A

DO - 10.1002/(SICI)1097-0215(19971104)73:3<367::AID-IJC11>3.0.CO;2-A

M3 - Article

C2 - 9359484

AN - SCOPUS:0030781397

VL - 73

SP - 367

EP - 370

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -